4-aminopyridine
4-Aminopyridine (4-AP) is an organic compound with the chemical formula H2NC5H4N. It is one of the three isomeric aminopyridines. It is used as a research tool in characterizing subtypes of the potassium channel. It has also been used as a drug, to manage some of the symptoms of multiple sclerosis, and is indicated for symptomatic improvement of walking in adults with several variations of the disease. It was undergoing Phase III clinical trials as of 2008, and the U.S. Food and Drug Administration (FDA) approved the compound on January 22, 2010. Fampridine is also marketed as Ampyra in the United States by Acorda Therapeutics and as Fampyra in the European Union, Canada, and Australia. In Canada, the medication has been approved for use by Health Canada since February 10, 2012. — Wikipedia
Clinical trial activity
8 trials · 13 clinical orgs · 0 marketing orgs
Earliest trial started Dec 12, 2018 (NCT03847545)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- Wikipedia4-Aminopyridine ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07171203 | Phase 1 | Dec 31, 2025 | University of California, San Diego |
| NCT07185347 | Phase 3 | Oct 1, 2025 | Assistance Publique - Hôpitaux de Paris |
| NCT06751784 | Phase 2 | Apr 30, 2025 | University of Basel |
| NCT05274477 | N/A | Jun 28, 2022 | University of Basel |
| NCT04652557 | Phase 2 | Mar 1, 2021 | University of Basel |
| NCT04516603 | Phase 2 | Oct 1, 2020 | University of Basel |
| NCT04148781 | Early Phase 1 (Phase 1) | Nov 30, 2019 | University of Western Ontario |
| NCT03847545 | N/A | Dec 12, 2018 | Fonden for scleroseramte paa Fyn, Region of Southern Denmark, Region Syddanmark, The Augustinus Foundation, Denmark., The Danish Multiple Sclerosis Society, The Foundation of Lily Benthine Lund, The Lounkaer Foundation, University of Miami, University of Southern Denmark |
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Basel | Academic/Hospital | 4 | 4 | 2 | 2020 |
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Fonden for scleroseramte paa Fyn | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Region of Southern Denmark | Government | 1 | 0 | 1 | 2018 |
| Region Syddanmark | Academic/Hospital | 1 | 0 | 1 | 2018 |
| The Augustinus Foundation, Denmark. | Academic/Hospital | 1 | 0 | 1 | 2018 |
| The Danish Multiple Sclerosis Society | Academic/Hospital | 1 | 0 | 1 | 2018 |
| The Foundation of Lily Benthine Lund | Academic/Hospital | 1 | 0 | 1 | 2018 |
| The Lounkaer Foundation | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of California, San Diego | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Miami | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Southern Denmark | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Western Ontario | Academic/Hospital | 1 | 1 | 1 | 2019 |